AbOliGo - fast, reproducible, antibody-oligo conjugates for all
AbOliGo is a company developing a revolutionary approach for rapid production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexed protein analysis, proteomics and spatial biology.
We believe AOCs are the ultimate detection tool for studying proteins and proteomes. They are revolutionizing multiplex assays by supercharging trusted antibodies - the Ab gives target-specific binding while the Oligo allows amplification and molecular barcoding. Our mission is to empower scientists by providing fast, reproducible, antibody-oligo conjugates (AOCs) for all.
A novel conjugation methodology that enables production at µg scale.
Develop a QC quantitative release criteria,
guaranteeing batch consistency.
Speed
Manufacture and deliver AOCs from a large portfolio within 3 days.
This will be achieved through three key technological advances
Custom Services
AOCs are complex, tunable reagents demanding a novel manufacturing approach, which we are happy to provide through our custom services.
About Us
A team dedicated to delivering consistent Antibody-Oligo Conjugates
Dr Brian Carpenter
CEO & Co-Founder
Brian has over twenty years of rich, commercial experience within the life science industry working for innovative, progressive companies such as Abcam and Innova Biosciences. During his last tenure, as a Product Director he was responsible for product life cycle management of the OEM primary antibodies, secondaries and primary conjugates.
Brian was the first commercial employee of Innova Biosciences who built and crafted the company’s go to market strategy for Pharma, Biotech and Academic customers.
Mick Knowles
Head of Reagents & Co-Founder
Mick Knowles has over twenty years of conjugation expertise, is a named inventor on several conjugation patents (conjugation kits), and was the lead R&D scientist for Innova Biosciences developing and launching 90% of products including antibody-oligo conjugates for the top 3 multiplex platforms.
As well as being a highly successful R&D scientist, Mick has a rich operational background which includes implementing and scaling manufacturing processes during rapid company growth stages, successfully building highly engaged and motivated teams, being in charge of multi-million-pound budgets, and designing/implementing/maintaining ISO quality systems.
Dr Nicholas Hutchings
Chairman & Co-Founder
Nick is a serial entrepreneur who has successfully launched and sold two antibody businesses. Most recently Absolute Antibody, a company which pioneered the development and supply of recombinant antibodies for research and diagnosis, as well as providing protein engineering services for therapeutics. Investors got a return of 8x - 42x (depending on round) and employees shared an option pool of over £4 million.
Nick studied Biochemistry at the University of Oxford followed by a doctorate at the Sir William Dunn School of Pathology supervised by Prof Neil Barclay.
Dr Nick Gee
Scientific Advisor & Co-Founder
Dr. Nick Gee founded Innova Biosciences in 2002, revolutionizing the antibody conjugation market with a user-friendly kit that produced antibody conjugates in just 20 minutes, requiring only 30 seconds of hands-on time and no specialist skills. Innova Biosciences was acquired by Expedeon in 2017.
Nick is a biochemist who has over twenty-five years of experience in conjugation chemistry, and is a named inventor on several patents related to novel conjugation methodologies.